Testing efgartigimod for systemic sclerosis
Treatments studied
Part of Skin clinical trials.
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have a diagnosis of systemic sclerosis (either the limited or diffuse type)
- You must have a positive ANA blood test with a titer of at least 1:160
- You must have a skin score between 15 and 35 on a specific measure called mRSS
- You must have had your first non-Raynaud symptom (like skin tightening) within the last 5 years if you test negative for anti-RNA polymerase III, or within the last 2 years if you test positive
- You must not have had a severe blood vessel problem in your fingers in the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether blocking a protein called TL1A can help reduce skin thickening and improve the immune system in people with systemic sclerosis (a condition where skin becomes hard and thick). Researchers will compare skin and blood samples from people with systemic sclerosis to healthy volunteers.
This trial tests a new drug, GB261, for people with systemic sclerosis (a condition that causes thickening and hardening of the skin and can affect internal organs). It aims to see if it can help when other treatments haven't worked well enough.
This trial tests a new investigational medicine called PRO-203 for people with systemic sclerosis (scleroderma). It aims to see if the medicine can help control active disease that hasn't responded to other treatments.
This trial tests whether special cells from umbilical cord (UC-MSC) can help treat systemic sclerosis—a disease that causes skin and organ hardening. If you have early systemic sclerosis that hasn't improved enough with standard treatments, this study may offer a new option.
This trial tests a new treatment called OL-CD19-GDT for people with systemic sclerosis or Sjögren's syndrome that hasn't responded to standard therapies. It aims to see if the treatment is safe and might help control the disease.
This study tests a new cell therapy called CD19 CAR-T for patients with systemic sclerosis that hasn't improved with standard treatments. The therapy aims to help reduce skin tightening and other symptoms.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.